| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P50 | author | Jos Kleijnen | Q28037365 |
| Adrián Vladimir Hernández | Q37840499 | ||
| Penny F Whiting | Q54936317 | ||
| Kate Misso | Q55454797 | ||
| Shona Lang | Q58414505 | ||
| P2093 | author name string | Sohan Deshpande | |
| Steven Duffy | |||
| Marie Westwood | |||
| Robert F Wolff | |||
| Steve Ryder | |||
| Marcello Di Nisio | |||
| J Christiaan Keurentjes | |||
| Simone Schmidlkofer | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 2456-2473 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Cannabinoids for Medical Use: A Systematic Review and Meta-analysis | |
| P478 | volume | 313 |
| Q91810662 | "Tea" time? Cannabis legalization in Canada |
| Q95270490 | A Balanced Approach for Cannabidiol Use in Chronic Pain |
| Q90263162 | A Cross-Sectional Study of Cannabidiol Users |
| Q45067497 | A Metabolomic Approach Applied to a Liquid Chromatography Coupled to High-Resolution Tandem Mass Spectrometry Method (HPLC-ESI-HRMS/MS): Towards the Comprehensive Evaluation of the Chemical Composition of Cannabis Medicinal Extracts. |
| Q64109830 | A Review of Cannabis in Chronic Kidney Disease Symptom Management |
| Q48134054 | A Systematic Review and Meta-Analysis of the In Vivo Haemodynamic Effects of Δ⁸-Tetrahydrocannabinol |
| Q47101767 | A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders |
| Q64284395 | A commentary on the medicinal use of marijuana |
| Q92187135 | A meta-analytic investigation of the associations between cannabis use and cannabis-related negative consequences |
| Q92335571 | A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol |
| Q41537590 | A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics |
| Q92433631 | A review of the anesthetic implications of marijuana use |
| Q61445273 | A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers |
| Q36386332 | A systematic review of the asymmetric inheritance of cellular organelles in eukaryotes: A critique of basic science validity and imprecision. |
| Q92035200 | Acute and short-term administrations of delta-9-tetrahydrocannabinol modulate major gut metabolomic regulatory pathways in C57BL/6 mice |
| Q55334438 | Addictive potential of novel treatments for refractory depression and anxiety. |
| Q91731937 | Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials |
| Q38855100 | An Exploratory Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treatment of Neuropathic Pain From Spinal Cord Injury and Disease |
| Q49689310 | Anesthetic implications of recreational drug use. |
| Q91583578 | Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders |
| Q89476992 | Applications of Yeast Synthetic Biology Geared towards the Production of Biopharmaceuticals |
| Q60962931 | Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis: A Systematic Review and Meta-analysis |
| Q93030201 | Association of Cannabinoid Administration With Experimental Pain in Healthy Adults: A Systematic Review and Meta-analysis |
| Q46938716 | Associations between medical cannabis and other drug use among unstably housed women |
| Q44351006 | Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study |
| Q50103603 | Attitudes of Irish patients with chronic pain towards medicinal cannabis |
| Q30826674 | Autophagy activation by novel inducers prevents BECN2-mediated drug tolerance to cannabinoids |
| Q92450859 | Benefit of Tetrahydrocannabinol versus Cannabidiol for Common Palliative Care Symptoms |
| Q91863774 | Benefits and harms of medical cannabis: a scoping review of systematic reviews |
| Q26998841 | Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review |
| Q39131734 | Building smart cannabis policy from the science up. |
| Q91789081 | Canadian Association of Gastroenterology Position Statement: Use of Cannabis in Gastroenterological and Hepatic Disorders |
| Q92302097 | Cannabidiol (CBD) Consumption and Perceived Impact on Extrahepatic Symptoms in Patients with Autoimmune Hepatitis |
| Q92647729 | Cannabidiol (CBD) for Treatment of Neurofibromatosis-related Pain and Concomitant Mood Disorder: A Case Report |
| Q91045445 | Cannabidiol Regulates Gene Expression in Encephalitogenic T cells Using Histone Methylation and noncoding RNA during Experimental Autoimmune Encephalomyelitis |
| Q47668118 | Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome |
| Q60929290 | Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain |
| Q39021787 | Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation? |
| Q42129148 | Cannabinoid 1 receptor knockout mice display cold allodynia, but enhanced recovery from spared-nerve injury-induced mechanical hypersensitivity. |
| Q57148532 | Cannabinoid Delivery Systems for Pain and Inflammation Treatment |
| Q34547759 | Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review |
| Q39360870 | Cannabinoid Receptor Signaling in Central Regulation of Feeding Behavior: A Mini-Review |
| Q26745261 | Cannabinoid receptor type-1: breaking the dogmas |
| Q92401471 | Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases |
| Q59808648 | Cannabinoids and Pain: New Insights From Old Molecules |
| Q57165566 | Cannabinoids and gastrointestinal motility: Pharmacology, clinical effects, and potential therapeutics in humans |
| Q38651395 | Cannabinoids and the Kidney: Effects in Health and Disease |
| Q90054153 | Cannabinoids as an Alternative Option for Conventional Analgesics in Cancer Pain Management: A Pharmacogenomics Perspective |
| Q48150492 | Cannabinoids concentration variability in cannabis olive oil galenic preparations |
| Q89161237 | Cannabinoids for Treatment of MS Symptoms: State of the Evidence |
| Q26472068 | Cannabinoids for chronic neuropathic pain |
| Q38566169 | Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease |
| Q94337892 | Cannabinoids for the treatment of dementia |
| Q78878849 | Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis |
| Q89047296 | Cannabinoids for the treatment of rheumatic diseases - where do we stand? |
| Q38918638 | Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? |
| Q39036791 | Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis |
| Q90011208 | Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis |
| Q41560629 | Cannabinoids in Medical Practice |
| Q42682955 | Cannabinoids in Pain Management and Palliative Medicine |
| Q33806487 | Cannabinoids in Pediatrics. |
| Q39177603 | Cannabinoids in palliative care: Systematic review and meta-analysis of efficacy, tolerability and safety |
| Q39004651 | Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases |
| Q89468008 | Cannabinoids in the descending pain modulatory circuit: Role in inflammation |
| Q38748394 | Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? |
| Q90400367 | Cannabinoids, Blood-Brain Barrier, and Brain Disposition |
| Q90450503 | Cannabinoids, Pain, and Opioid Use Reduction: The Importance of Distilling and Disseminating Existing Data |
| Q37630787 | Cannabis Epidemiology: A Selective Review. |
| Q44349195 | Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States |
| Q50025597 | Cannabis Use is Associated with Lower Odds of Prescription Opioid Analgesic Use Among HIV-Infected Individuals with Chronic Pain. |
| Q54398076 | Cannabis Use, Medication Management and Adherence Among Persons Living with HIV. |
| Q43075872 | Cannabis and Cannabinoids for Chronic Pain |
| Q90435616 | Cannabis and Cannabinoids in Mood and Anxiety Disorders: Impact on Illness Onset and Course, and Assessment of Therapeutic Potential |
| Q64108597 | Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination |
| Q89526801 | Cannabis and Pain Treatment-A Review of the Clinical Utility and a Practical Approach in Light of Uncertainty |
| Q39150465 | Cannabis and Pain: A Clinical Review |
| Q55090140 | Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms a Mile High. |
| Q64889332 | Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. |
| Q90626055 | Cannabis and mental illness: a review |
| Q38598485 | Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report |
| Q94079262 | Cannabis conundrum |
| Q41989040 | Cannabis for the Treatment of Chronic Pain in the Era of an Opioid Epidemic: A Symposium-Based Review of Sociomedical Science |
| Q58578345 | Cannabis for the treatment of Crohn's disease |
| Q58578364 | Cannabis for the treatment of ulcerative colitis |
| Q94347980 | Cannabis for the treatment of ulcerative colitis |
| Q91041824 | Cannabis in psychiatric disorders: the cart before the horse? |
| Q88907845 | Cannabis regulatory science: risk-benefit considerations for mental disorders |
| Q57671702 | Cannabis shenanigans: advocating for the restoration of an effective treatment of pain following spinal cord injury |
| Q89569085 | Cannabis use among U.S. adolescents in the era of marijuana legalization: a review of changing use patterns, comorbidity, and health correlates |
| Q46905530 | Cannabis use disorder and male sex predict medical cannabis card status in a sample of high risk adolescents |
| Q90244124 | Cannabis use in cancer: a survey of the current state at BC Cancer before recreational legalization in Canada |
| Q47139391 | Cannabis, cannabinoids, and health |
| Q47770249 | Cannabis-Associated Asthma and Allergies |
| Q91897310 | Cannabis-based medicines and the perioperative physician |
| Q56815074 | Cannabis-based medicines for chronic neuropathic pain in adults |
| Q40443401 | Cannabis: a self-medication drug for weight management? The never ending story. |
| Q57020541 | Characteristics and Patterns of Marijuana Use in Community-Dwelling Older Adults |
| Q93081422 | Chronic Pain: Structural and Functional Changes in Brain Structures and Associated Negative Affective States |
| Q48034511 | Clearing the air: discrepant policy and practice concerning neonatal cannabinoid exposure |
| Q38977158 | Clearing the haze: the complexities and challenges of research on state marijuana laws |
| Q52315890 | Clinical and functional outcomes of cannabis use among individuals with anxiety disorders: A 3-year population-based longitudinal study. |
| Q34535259 | Clinical applications of hallucinogens: A review |
| Q39484634 | Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation |
| Q37082254 | Colorado Cannabis Legalization and Its Effect on Emergency Care |
| Q57801577 | Combined THC and CBD to treat pain in epidermolysis bullosa: a report of three cases |
| Q37108856 | Combined effects of HIV and marijuana use on neurocognitive functioning and immune status |
| Q53195107 | Commentary: Navigating the complexities of marijuana. |
| Q91987015 | Complete biosynthesis of cannabinoids and their unnatural analogues in yeast |
| Q38943088 | Concise review of the management of iatrogenic emesis using cannabinoids: emphasis on nabilone for chemotherapy-induced nausea and vomiting |
| Q34543208 | Crystal Structure of the Human Cannabinoid Receptor CB1. |
| Q47958585 | Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings |
| Q58552712 | DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults |
| Q99408004 | Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints |
| Q89830884 | Deficits in pain medication in older adults with chronic pain receiving home care: A cross-sectional study in Germany |
| Q89329527 | Delta-9-tetrahydrocannabinol and cannabidiol: Separating the chemicals from the "weed," a pharmacodynamic discussion |
| Q50960906 | Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas Chromatography-Tandem Mass Spectrometry. |
| Q91781582 | Development of Standard Operating Protocols for the Optimization of Cannabis-Based Formulations for Medical Purposes |
| Q92084348 | Diverse TRPV1 responses to cannabinoids |
| Q47378983 | Does Cannabis Use Cause Declines in Neuropsychological Functioning? A Review of Longitudinal Studies |
| Q90169566 | Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I/II randomised placebo controlled trial |
| Q64937351 | Does cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA. |
| Q42361380 | Drug Vaping: From the Dangers of Misuse to New Therapeutic Devices. |
| Q90654618 | Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations |
| Q92064800 | Early life stress and development of the endocannabinoid system: A bidirectional process in programming future coping |
| Q89432627 | Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study |
| Q89575244 | Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions |
| Q92237045 | Effects of cannabinoid administration for pain: A meta-analysis and meta-regression |
| Q90361591 | Efficacy of Dronabinol for Acute Pain Management in Adults with Traumatic Injury: Study Protocol of A Randomized Controlled Trial |
| Q38696763 | Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials |
| Q50072369 | Efficacy, tolerability and safety of cannabis-based medicines for chronic pain management - An overview of systematic reviews |
| Q35898479 | Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews |
| Q47669922 | Emergency Department Burden of Nausea and Vomiting Associated With Cannabis Use Disorder: US Trends From 2006 to 2013. |
| Q55004485 | Emerging Topics and Innovative Methodologies in Cannabis Research. |
| Q38623570 | Emerging Treatments for Neuropathic Pain |
| Q39336572 | Endocannabinoid Signaling in the Control of Social Behavior |
| Q38916196 | Endocannabinoid system: Role in depression, reward and pain control (Review). |
| Q90021525 | Ensuring access to safe, effective, and affordable cannabis-based medicines |
| Q49951958 | Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States |
| Q56968125 | European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management |
| Q64866238 | Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders |
| Q57841729 | Examining the blurred boundaries between medical and recreational cannabis – results from an international study of small-scale cannabis cultivators |
| Q59791745 | Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression |
| Q38830379 | Exploring Marijuana Advertising on Weedmaps, a Popular Online Directory |
| Q91822788 | Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders |
| Q90321305 | Extractions of Medical Cannabis Cultivars and the Role of Decarboxylation in Optimal Receptor Responses |
| Q64273230 | False News of a Cannabis Cancer Cure |
| Q92512958 | Flavonoid Derivative of Cannabis Demonstrates Therapeutic Potential in Preclinical Models of Metastatic Pancreatic Cancer |
| Q30241053 | Focus on cannabinoids and synthetic cannabinoids |
| Q47570053 | Frequency of Cannabis Use Among Primary Care Patients in Washington State |
| Q37663920 | Genetic variation in the endocannabinoid system and response to Cognitive Behavior Therapy for child anxiety disorders |
| Q93163026 | Genome-wide DNA methylation analysis of heavy cannabis exposure in a New Zealand longitudinal cohort |
| Q28274406 | Genome-wide association study of lifetime cannabis use based on a large meta-analytic sample of 32 330 subjects from the International Cannabis Consortium |
| Q62019874 | Gilles de la Tourette syndrome |
| Q28392199 | HIV-1, methamphetamine and astrocytes at neuroinflammatory Crossroads |
| Q64065908 | Health professional beliefs, knowledge, and concerns surrounding medicinal cannabis - A systematic review |
| Q47633702 | High Hope for Medical Marijuana in Digestive Disorders |
| Q38784874 | High times for cannabis: Epigenetic imprint and its legacy on brain and behavior |
| Q90331172 | High-Frequency Medical Cannabis Use Is Associated With Worse Pain Among Individuals With Chronic Pain |
| Q47562252 | History of marijuana use does not affect outcomes on the liver transplant waitlist |
| Q39580639 | Illicit Substance Use in US Adults With Chronic Low Back Pain |
| Q89340947 | Impact of cannabis legalization on treatment and research priorities for cannabis use disorder |
| Q49788859 | Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability |
| Q90522446 | Influence of Altitude on Phytochemical Composition of Hemp Inflorescence: A Metabolomic Approach |
| Q98286403 | Inhibition of striatonigral autophagy as a link between cannabinoid intoxication and impairment of motor coordination |
| Q36685151 | Integrating cannabis into clinical cancer care |
| Q47881378 | Is 2-Hydroxypropyl-β-cyclodextrin a Suitable Carrier for Central Administration of Δ9 -Tetrahydrocannabinol? Preclinical Evidence |
| Q92750122 | Is marijuana use associated with lower inflammation? Results from waves III and IV of the national longitudinal study of adolescent to adult health |
| Q40013703 | Is the Hype of Medical Marijuana All Smoke and Mirrors? |
| Q36592915 | Is the medical use of cannabis a therapeutic option for children? |
| Q39098495 | Is there a role for cannabidiol in psychiatry? |
| Q34521105 | Keep off the grass? Cannabis, cognition and addiction |
| Q89408732 | Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey |
| Q46449901 | Labeling Accuracy of Cannabidiol Extracts Sold Online |
| Q99711797 | Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products |
| Q45922717 | Le cannabis à des fins médicales est-il une option pour les enfants? |
| Q33575724 | Leaner and greener analysis of cannabinoids |
| Q38973739 | Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target |
| Q58252786 | Leveraging user perspectives for insight into cannabis concentrates |
| Q38373240 | Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. |
| Q88304662 | Marijuana Promotion Online: an Investigation of Dispensary Practices |
| Q89389849 | Marijuana matters: reviewing the impact of marijuana on cognition, brain structure and function, & exploring policy implications and barriers to research |
| Q37609250 | Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database |
| Q89575839 | Marijuana, Lower Urinary Tract Symptoms, and Pain in the Urologic Patient |
| Q90182513 | Matched pilot study examining cannabis-based dronabinol for acute pain following traumatic injury |
| Q100684185 | Medical Cannabis Treatment for Chronic Pain: Outcomes and Prediction of Response |
| Q89505965 | Medical Cannabis Use Among Individuals With Cancer: An Unresolved and Timely Issue |
| Q39291272 | Medical Marijuana and Marijuana Legalization. |
| Q49937440 | Medical Marijuana: Current Concepts, Pharmacological Actions of Cannabinoid Receptor Mediated Activation, and Societal Implications |
| Q34540978 | Medical Marijuana: Just the Beginning of a Long, Strange Trip? |
| Q64907967 | Medical Oncologists' Beliefs, Practices, and Knowledge Regarding Marijuana Used Therapeutically: A Nationally Representative Survey Study. |
| Q58102489 | Medical Use of Cannabinoids |
| Q88644500 | Medical cannabinoids |
| Q90173408 | Medical cannabis for chronic pain: can it make a difference in pain management? |
| Q97523155 | Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use? |
| Q98157760 | Medical cannabis for the reduction of opioid dosage in the treatment of non-cancer chronic pain: a systematic review |
| Q89493872 | Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014 |
| Q49609463 | Medical cannabis: A forward vision for the clinician |
| Q58656073 | Medical cannabis: aligning use to evidence-based medicine approach |
| Q38724380 | Medical cannabis: considerations for the anesthesiologist and pain physician |
| Q89535262 | Medical marijuana and workers' compensation claiming |
| Q41298087 | Medical marijuana for the treatment of vismodegib-related muscle spasm. |
| Q89012785 | Medical marijuana for urologic chronic pelvic pain |
| Q47941145 | Medical marijuana in pediatric oncology: A review of the evidence and implications for practice |
| Q50104956 | Medical marijuana laws and adolescent marijuana use in the United States: A systematic review and meta-analysis |
| Q46042073 | Medical marijuana: Showdown at the cannabis corral |
| Q99578821 | Medical, therapeutic, and recreational use of cannabis among young men who have sex with men living with HIV |
| Q92707688 | Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review |
| Q64075416 | Medicinal use of cannabis based products and cannabinoids |
| Q52649585 | Meta-analysis of the relationship between single nucleotide polymorphism of IL-10-1082G/A and rheumatic heart disease. |
| Q64259803 | Modulation of the Endocannabinoid System as a Potential Anticancer Strategy |
| Q93020002 | Nabilone administration in refractory chronic diarrhea: a case series |
| Q42156032 | Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids |
| Q47652702 | Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential |
| Q47862105 | Neuroimaging meta-analysis of cannabis use studies reveals convergent functional alterations in brain regions supporting cognitive control and reward processing. |
| Q39169582 | Neuropathic Pain Treatment: Still a Challenge |
| Q52584175 | New York Physicians' Perspectives and Knowledge of the State Medical Marijuana Program. |
| Q38747582 | Non-opioid medications for the relief of chronic breathlessness: current evidence |
| Q36837691 | Older, Less Regulated Medical Marijuana Programs Have Much Greater Enrollment Rates Than Newer 'Medicalized' Programs |
| Q50155110 | Ongoing strategies and updates on pain management in gynecologic oncology patients |
| Q92744802 | Online patient-provider cannabis consultations |
| Q37675722 | Opioids Out, Cannabis In: Negotiating the Unknowns in Patient Care for Chronic Pain |
| Q92627340 | Opportunities for cannabis in supportive care in cancer |
| Q52617829 | Optimal pain management for patients with cancer in the modern era. |
| Q59810580 | Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q91763202 | Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo controlled, randomised clinical trial of efficacy and safety of cannabidiol (CBD) |
| Q97419460 | Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabi |
| Q49487194 | PTL401, a New Formulation Based on Pro-nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers |
| Q60922417 | Pain Management and Opioid Regulation: Continuing Public Health Challenges |
| Q43075585 | Pain Management for Primary Care Providers: A Narrative Review of High-Impact Studies, 2014-2016. |
| Q49422188 | Pain medication and long QT syndrome. |
| Q58698085 | Patient-Reported Symptom Relief Following Medical Cannabis Consumption |
| Q44351197 | Patterns and correlates of medical cannabis use for pain among patients prescribed long-term opioid therapy |
| Q64085601 | Patterns of Marijuana Use and Health Impact: A Survey Among Older Coloradans |
| Q38693941 | Patterns of Twitter Behavior Among Networks of Cannabis Dispensaries in California. |
| Q55333056 | Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. |
| Q92168693 | Perceived safety of cannabis intoxication predicts frequency of driving while intoxicated |
| Q90394452 | Perceptions of the Comparative Safety of Different Forms of Marijuana Use Among the Adult US Population |
| Q60313531 | Personal experience and attitudes of pain medicine specialists in Israel regarding the medical use of cannabis for chronic pain |
| Q47958282 | Perspective: Close the knowledge gap. |
| Q60303341 | Pharmaceutical cannabinoid use in Manitoba, 2004/05 to 2014/15: a population-based cross-sectional study |
| Q57176921 | Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study |
| Q90256765 | Pharmacy Student Knowledge, Confidence and Attitudes Toward Medical Cannabis and Curricular Coverage |
| Q89389653 | Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain |
| Q91290912 | Positive and Negative Effects of Cannabis and Cannabinoids on Health |
| Q90321309 | Potency Analysis of Medical Marijuana Products from New York State |
| Q89529093 | Potency Assessment of CBD Oils by Their Effects on Cell Signaling Pathways |
| Q91746887 | Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use |
| Q98779243 | Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain |
| Q91803933 | Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders |
| Q47655800 | Prevalence and correlates of "Vaping" as a route of cannabis administration in medical cannabis patients |
| Q47634651 | Prevalence and correlates of sleep-related problems in adults receiving medical cannabis for chronic pain |
| Q55437930 | Priority areas for cannabis and cannabinoid product research in South Africa. |
| Q64247701 | Prolonged Cannabidiol Treatment Lacks on Detrimental Effects on Memory, Motor Performance and Anxiety in C57BL/6J Mice |
| Q64245770 | Prospects for the Use of Cannabinoids in Oncology and Palliative Care Practice: A Review of the Evidence |
| Q47547939 | Provider Perspectives on Use of Medical Marijuana in Children With Cancer |
| Q30377895 | Public health and international drug policy. |
| Q90968352 | Public health implications of legalising the production and sale of cannabis for medicinal and recreational use |
| Q60536257 | Quality Traits of "Cannabidiol Oils": Cannabinoids Content, Terpene Fingerprint and Oxidation Stability of European Commercially Available Preparations |
| Q26766090 | Recent Advances in Understanding and Managing Tourette Syndrome |
| Q39424734 | Recent advances in understanding and managing cancer pain |
| Q38605377 | Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. |
| Q55892293 | Release the strains |
| Q55225261 | Religious Involvement and Marijuana Use for Medical and Recreational Purposes. |
| Q90318457 | Reviewing the Potential of Psychedelics for the Treatment of PTSD |
| Q92702296 | Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain |
| Q52662505 | Self-medication of mood and anxiety disorders with marijuana: Higher in states with medical marijuana laws. |
| Q48234381 | Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective |
| Q94069931 | Should Medical Cannabis Administered by Inhalation Be Allowed for Hospitalized Patients? |
| Q49961374 | Simplified guideline for prescribing medical cannabinoids in primary care |
| Q36618089 | Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability |
| Q48325031 | Single-Dose Pharmacokinetics of Oral Cannabidiol Following Administration of PTL101: A New Formulation Based on Gelatin Matrix Pellets Technology |
| Q92812708 | Sleep deficiency and chronic pain: potential underlying mechanisms and clinical implications |
| Q60916595 | Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55 |
| Q37336806 | Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function |
| Q93189553 | State marijuana laws and opioid overdose mortality |
| Q38676452 | State of the Art Antiemetic Therapy for Cancer Patients. |
| Q57819448 | Stop the Attack on Minnesota's Courageous Stance to Allow Its Residents to Sleep Safely |
| Q39038691 | Structural plasticity and reorganisation in chronic pain |
| Q90975764 | Structure of an allosteric modulator bound to the CB1 cannabinoid receptor |
| Q38732849 | Substance Use Disorder Treatment Following Clinician-Initiated Discontinuation of Long-Term Opioid Therapy Resulting from an Aberrant Urine Drug Test |
| Q91649674 | Substance use consequences, mental health problems, and readiness to change among Veterans seeking substance use treatment |
| Q37365243 | Supplementary searches of PubMed to improve currency of MEDLINE and MEDLINE In-Process searches via Ovid. |
| Q60937768 | Synthetic Cannabinoid Activity Against Colorectal Cancer Cells |
| Q55384363 | Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. |
| Q39150365 | Systematic Review of the Costs and Benefits of Prescribed Cannabis-Based Medicines for the Management of Chronic Illness: Lessons from Multiple Sclerosis |
| Q50201189 | Systematic review and meta-analysis of cannabinoids in palliative medicine |
| Q49961204 | Systematic review of systematic reviews for medical cannabinoids: Pain, nausea and vomiting, spasticity, and harms |
| Q28554883 | Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development |
| Q90359017 | Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain |
| Q89861376 | Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain |
| Q57174777 | Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models |
| Q89925191 | Tasty THC: Promises and Challenges of Cannabis Edibles |
| Q55026293 | The Cannabinoid Content of Legal Cannabis in Washington State Varies Systematically Across Testing Facilities and Popular Consumer Products. |
| Q38600704 | The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. |
| Q88710043 | The Form and Content of Cannabis Products in the United States |
| Q41285812 | The Protective Behavioral Strategies for Marijuana Scale: Further examination using item response theory |
| Q36015888 | The Role of Medicinal Cannabis in Clinical Therapy: Pharmacists' Perspectives |
| Q38822341 | The Role of the Endocannabinoid System in the Brain-Gut Axis |
| Q99566335 | The Times They Are A-Changin': Knowledge and Perceptions Regarding Medical Cannabis in an Academic Family Medicine Department |
| Q50016902 | The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews |
| Q42714638 | The Use of Cannabis by Patients with Sickle Cell Disease Increased the Frequency of Hospitalization due to Vaso-Occlusive Crises |
| Q38842133 | The Use of Medical Marijuana in Cancer |
| Q58779432 | The adverse health effects and harms related to marijuana use: an overview review |
| Q59067445 | The cannabis crop |
| Q49961496 | The cannabis paradox |
| Q87871377 | The case for medicinal cannabis |
| Q55415383 | The current state and future perspectives of cannabinoids in cancer biology. |
| Q38932637 | The current status of artisanal cannabis for the treatment of epilepsy in the United States |
| Q45047828 | The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice |
| Q38937293 | The gastrointestinal tract - a central organ of cannabinoid signaling in health and disease |
| Q92878674 | The nephrologist's guide to cannabis and cannabinoids |
| Q39758927 | The pattern of anxiolytic and hypnotic management by Australian general practice trainees |
| Q100401349 | The perils of recreational marijuana use: relationships with mental health among emergency department patients |
| Q52313456 | The potential impact of cannabis legalization on the development of cannabis use disorders. |
| Q92446152 | The use of cannabis in supportive care and treatment of brain tumor |
| Q89535798 | Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews |
| Q47622029 | Therapeutic use of cannabis: Prevalence and characteristics among adults in Ontario, Canada. |
| Q47561523 | Time to acknowledge the mixed effects of cannabis on health: a summary and critical review of the NASEM 2017 report on the health effects of cannabis and cannabinoids. |
| Q89640642 | Toward a Patient Registry for Cannabis Use: An Exploratory Study of Patient Use in an Outpatient Health-Care Clinic in Oregon |
| Q88658966 | Toward a Shared-Care Model of Relapsing-Remitting Multiple Sclerosis: Role of the Primary Care Practitioner |
| Q37302123 | Tracking Dabbing Using Search Query Surveillance: A Case Study in the United States. |
| Q58775742 | Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis |
| Q41152416 | Training and Practices of Cannabis Dispensary Staff |
| Q40190400 | Trends in registered medical marijuana participation across 13 US states and District of Columbia. |
| Q40065249 | U.S. Epidemiology of Cannabis Use and Associated Problems |
| Q99553751 | Understanding Cannabis-Based Therapeutics in Sports Medicine |
| Q96303345 | Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition |
| Q46968189 | Use of Cannabinoids for Spasticity and Pain Management in MS. |
| Q92606746 | Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement |
| Q90587176 | Use of marijuana exclusively for medical purposes |
| Q90838945 | Utilization of medicinal cannabis for pain by individuals with spinal cord injury |
| Q50087206 | Vaping medical marijuana |
| Q38757423 | Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state |
| Q60913118 | Weighing the Benefits and Risks of Medical Marijuana Use: A Brief Review |
| Q34524036 | Weighing the Evidence: A Systematic Review on Long-Term Neurocognitive Effects of Cannabis Use in Abstinent Adolescents and Adults |
| Q36522795 | What Do We Know Now About the Impact of the Laws Related to Marijuana? |
| Q38732467 | What do providers want to know about opioid prescribing? A qualitative analysis of their questions |
| Q90311957 | What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms? A comprehensive review |
| Q30241174 | What's New in Orthopaedic Rehabilitation |
| Q64979069 | Why Marijuana Will Not Fix the Opioid Epidemic. |
| Q89036142 | [Cannabinoids in pain medicine] |
| Q53637692 | [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies]. |
| Q90198190 | [Position paper on medical cannabis and cannabis-based medicines in pain medicine] |
| Q49961227 | Lignes directrices simplifiées en matière de prescription de cannabinoïdes médicaux en soins de première ligne. |
Search more.